Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 481 to 495 of 1422 results for social care

  1. Nemolizumab for treating prurigo nodularis [ID6451]

    In development [GID-TA11566] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  2. Seladelpar for previously treated primary biliary cholangitis ID6429

    In development [GID-TA11540] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  3. Our projects and partners

    NICE research projects and partners.

  4. Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]

    In development [GID-TA10930] Expected publication date: 28 May 2025

    Technology appraisal guidance
    In development

  5. Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation ID5073

    In development [GID-TA10959] Expected publication date: 23 July 2025

    Technology appraisal guidance
    In development

  6. Delgocitinib for treating moderate to severe chronic hand eczema ID6408

    In development [GID-TA11506] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Lung cancer in adults (QS17)

    This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    13 December 2019
    View quality statements

    Sections for QS17

  8. Public board meeting agenda and papers: November 2020

    Agenda and papers of the NICE public board meeting on 18 November 2020

  9. Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

    In development [GID-TA11221] Expected publication date: 26 March 2025

    Technology appraisal guidance
    In development

  10. Exagamglogene autotemcel for treating sickle cell disease [ID4016]

    In development [GID-TA11249] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ublituximab for treating relapsing multiple sclerosis [ID6350]

    In development [GID-TA11268] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    In development [GID-TA11228] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]

    In development [GID-TA10778] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221

    In development [GID-TA11183] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development